Optic IconOptic Logo
|
SearchCollectionsBenchmarks

abiraterone

1 product

54 abstracts

1 target

Target
CYP17,20 lyase
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).
Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).
Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.
Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Studienpraxis Urologie, Asan Medical Center, Hospital Universitario Gregorio Marañón,
Abstract
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.
Org: Rigshospitalet University Hospital of Copenhagen, HUCH, Finland, Tampere University Hospital (TAYS), Espoo,
Abstract
Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).
Org: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, Private Medical Institution, Euromed service, St Petersburg, Russian Federation, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain, Department Of Medicine, Norwalk Hospital, Nuvance Health, Norwalk, CT, Pfizer Inc., Collegeville, PA,
Abstract
A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.
Org: Michelson Center for Convergent Bioscience,
Abstract
Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): A pooled analysis of phase 2 trials.
Org: Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis, Department of Data Sciences, Beth Israel Deaconess Medical Center, University of California Irvine,
Abstract
A randomized phase II study of ADT + abiraterone versus ADT + abiraterone + docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer.
Org: Northwestern University, Feinberg School of Medicine,
Abstract
PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.
Org: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,
Abstract
A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).
Org: Catalan Institute of Cancer (ICO), Celcuity, Inc., Département Interdisciplinaire D’organisation Du Parcours Patient (DIOPP),
Abstract
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
Org: Saint Louis VA Medical Center, University of Massachusetts Lowell, St. Louis Veterans Affairs Medical Center,
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).
Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC).
Org: Chesapeake Urology Research Associates, Duke Cancer Network,
Abstract
Targeting androgen receptor signaling in glioblastoma: A novel biomarker and therapeutic approach.
Org: UNSW Sydney, St Vincent's Clinical School/Garvan Institute of Medical Research, QIMR Bergdorfer Medical Research Institute,
Abstract
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.
Org: Bayer Ltd, Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain,
Abstract
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).
Org: British Columbia Cancer Agency (BCCA), Vancouver Cancer Centre, Vancouver, BC, Canada, Huntsman Cancer Institute, Salt Lake City, UT, Cancer Institute Center for Prostate and Urologic Cancer, Duke University Medical Center, Durham, NC, Urologicum Duisburg, Duisburg, Germany, Centre Hospitalier de Quimper, Institut de Cancérologie de Cornouaille (ICC), Brest, France, Kagawa University, Kagawa, Japan, Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey, Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, AstraZeneca, Gaithersburg, MD, AstraZeneca, Cambridge, United Kingdom, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Prevalence of polypharmacy, drug-drug interactions, and inappropriate prescription in elderly patients with urological cancers.
Org: Hospital Universitario Marques Valdecilla, HUMV,
Abstract
4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.
Org: The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, NSW, Australia, St. Vincent's Hospital, Darlinghurst, NSW, Australia,
Abstract
Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.
Org: Johns Hopkins University School of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC).
Org: Centre Hospitalier de l’Université de Montréal/CRCHUM, Centro Integrado de Oncologia de Curitiba, Radboud Universitair Medisch Centrum, Southampton General Hospital, Centre Hospitalier de Quimper,
Abstract
Real-world treatment landscape in advanced metastatic castration resistant prostate cancer.
Org: Johnson & Johnson Consumer, Janssen Research and Development, Janssen Pharmaceuticals, Research & Development, Immutep, Saint-Aubin, France, Johnson and Johnson Innovative Medicine, Spring House, PA,
Abstract
Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial.
Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Beijing Biostar Pharmaceuticals,
Abstract
Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: The OPTYX study.
Org: University Hospitals Seidman Cancer Center and Case Western Reserve University, University of California, San Diego Health, Northwestern University Feinberg School of Medicine, Department of Urology, Chicago, IL, Chesapeake Urology, Sumitomo Pharma America,
Abstract
Comparison of prostate-specific antigen (PSA) response in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) vs abiraterone acetate (ABI): A real-world (RW) causal analysis.
Org: New Jersey Urology, A Summit Health Company, Rowan University School of Osteopathic Medicine, Towson, MD,
Abstract
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
Org: Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, UCI Health,
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, NewYork-Presbyterian/Weill Cornell Medical Center, Duke Cancer Institute, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Memorial Sloan Kettering Cancer Center,
Abstract
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
Org: Prostate Cancer Foundation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Mayo Clinic,
Abstract
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
Org: Carolina Urologic Research Center, Oncology Hematology Consultants Ltd., First Urology, Urology Cancer Center, PC, National Cancer Institute, Vilnius, Lithuania,
Abstract
mFAST-SeqS based aneuploidy score in circulating cell-free DNA and role as early response marker in patients with metastatic prostate cancer treated with androgen receptor signaling inhibitor.
Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Franciscus Gasthuis & Vlietland, Erasmus University Medical Center,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).
Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.
Org: Roswell Park Cancer Institute, Advanced Radiation Centers of New York, Bayer HealthCare Pharmaceuticals Inc., Bayer Consumer Care AG,
Abstract
Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.
Org: Fudan University Shanghai Cancer Center, Jiangsu Province Hospital, The Second Hospital of Tianjin Medical University, Department of Uro-Oncology, Chongqing University Cancer Hospital, Sichuan Provincial People's Hospital, Chengdu, China,
Abstract
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
Org: OHSU Knight Cancer Institute, Portland, OR, Boston University Chobanian & Avedisian School of Medicine, Exact Sciences Corporation, Oregon Health & Science University, University of Washington; Fred Hutchinson Cancer Center,
Abstract
Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with metastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.
Org: Fudan University Shanghai Cancer Center, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Association of dynamic changes in serological markers with survival in de novo metastatic hormone-sensitive prostate cancer.
Org: Rush University Medical Center, Case Western Reserve University School of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, UCLA Department of Radiation Oncology,
Abstract
Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs).
Org: Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, UTC Therapeutics, Hunstman Cancer Institute at the University of Utah, City of Hope Comprehensive Cancer Center,
Abstract
Treatment and survival of de novo metastatic hormone sensitive prostate cancer among African American US Veterans.
Org: Washington University School of Medicine in St Louis, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, Washington University in St. Louis, Siteman Cancer Center/Washington University,
Abstract
An analysis to inform the timing of docetaxel use leveraging data from the United States Veterans Administration on patients with metastatic castration-sensitive prostate cancer (mCSPC).
Org: Columbia University Medical Center, University of Nebraska Medical Center, Institute of Molecular Biology, Bulgarian Academy of Sciences, Columbia University Herbert Irving Comprehensive Cancer Center, James Peters Bronx Veterans Affairs Medical Center,
Abstract
Comparing the efficacy of abiraterone and enzalutamide in United States veterans with metastatic castration-sensitive prostate cancer (mCSPC) by estimating rates of tumor growth (g-rate).
Org: University of Nebraska Medical Center, Columbia University Medical Center, Institute of Molecular Biology, Bulgarian Academy of Sciences, James J. Peters VA Medical Center, Suny Downstate Health Sciences University,
Abstract
The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).
Org: Sorrento Therapeutics Inc., Sorrento Therapeutics, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke Cancer Institute, Carbone Cancer Center, University of Wisconsin, Madison, WI,
Abstract
Associations between androgen-directed treatments and AR mutational landscapes in the circulating tumor DNA of a real-world metastatic prostate cancer cohort.
Org: Tulane University, New Orleans, LA, Tempus Labs, Inc., Tulane Cancer Center,
Abstract
Enzalutamide vs abiraterone in patients with prostate cancer with and without type 2 diabetes mellitus.
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Thomas Jefferson University, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Pharmacology & Experimental Therapeutics, College of Computing and Informatics,
Abstract
Real world utilization and disparities in outcome in the use of novel anti-androgen agents for metastatic prostate cancer.
Org: Virginia Commonwealth University Health System, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Virginia Commonwealth University School of Medicine, VCU School of Medicine, Virginia Commonwealth University Medical Center,
Abstract
Feasibility of daily physical activity monitoring and associations with treatment toxicity in older adults with metastatic prostate cancer.
Org: University Health Network, Princess Margaret Cancer Centre, National Institute of Medical Sciences and Nutrition Salvador Zubirán, University of Toronto, Odette Cancer Centre,
Abstract
Survival of de novo metastatic hormone sensitive prostate cancer in US Veterans based on treatment and PSA at diagnosis.
Org: Saint Louis University School of Medicine, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, St. Louis University, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine,
Abstract
Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017-2023: An administrative claims database study.
Org: Bayer HealthCare Pharmaceuticals Inc., Bayer AG, Bayer Ltd, Bayer Consumer Care AG, Duke Cancer Institute Center for Prostate and Urologic Cancers,
Abstract
The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer: Secondary analysis of two randomized clinical trials.
Org: Fudan University Shanghai Cancer Center, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.
Org: Northshore University Health System, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Levine Cancer Institute, Atrium Health Carolinas Medical Center, Carolina Urologic Research Center,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).
Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer.
Org: Laboratoire Toxicomed, University of Tlemcen, Tidjani Damerdji Teaching Hospital, CHU Tlemcen,
Abstract
Clinical factors associated with prescribing patterns of bone modifying agents in men with metastatic castration-resistant prostate cancer.
Org: Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, Ann Arbor Veterans Health Administration, University of Wisconsin Madison School of Medicine and Public Health,
Abstract
Efficacy of PARP inhibitors in patients with metastatic castration resistant prostate carcinoma: A meta-analysis of phase III randomized controlled trials.
Org: Community Hospital of San Bernardino, Abbott Northwestern Hospital, SSM St Mary's hospital, University of California Riverside, SSM St Louis University hospital,
Product
Abiraterone acetate